Single Nucleotide Polymorphisms (SNPs) of URAT1 (rs7932775) and ABCG2 (rs3825016) on Chronic Kidney Disease Patients with Hyperuricemia
- 1 Nephrology Department, The Third People’s Hospital of Wuxi, The Third Affiliated Hospital of Nantong University, Wuxi, China
- 2 Nephrology Department, The Third People’s Hospital of Wuxi, The Third Affiliated Hospital of Nantong University, Wuxi, China
- 3 Nephrology Department, The Third People’s Hospital of Wuxi, The Third Affiliated Hospital of Nantong University, Wuxi, China
- 4 Nephrology Department, The Third People’s Hospital of Wuxi, The Third Affiliated Hospital of Nantong University, Wuxi, China
- 5 Nephrology Department, The Third People’s Hospital of Wuxi, The Third Affiliated Hospital of Nantong University, Wuxi, China
- 6 Nephrology Department, The Third People’s Hospital of Wuxi, The Third Affiliated Hospital of Nantong University, Wuxi, China
- 7 Nephrology Department, The Third People’s Hospital of Wuxi, The Third Affiliated Hospital of Nantong University, Wuxi, China
- 8 Nephrology Department, The Third People’s Hospital of Wuxi, The Third Affiliated Hospital of Nantong University, Wuxi, China
Abstract
Background: More and more chronic kidney disease (CKD) patients are accompanied with hyperuricaemia. As is known, hyperuricaemia is an independent hazard of both cardiovascular diseases (CVD) and chronic kidney diseases. We aim at identifying Single Nucleotide Polymorphism (SNP) difference of hURAT1 (rs7932775) and ABCG2 (rs3825016) on CKD patient with hyperuricemia and/or gout. Methods : All forty-two CKD patients were divided into two groups : hyperuricemia, and control group. 24 hour s urine sample and serum were prepared for testing biochemistry parameters. The polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) method is used to anal yze hURAT1 and ABCG2 single nucleotide polymorphisms in different group s . Results: 17 patients have CT SNP of hURAT1 (rs7932775) and 13 patients have CT SNP of ABCG2 (rs3825016) in hyperuricemia group, while only 5 persons and 6 persons have the same mutations in control group respectively. 7 patients have CT SNP of both hURAT1 (rs7932775) and ABCG2 (rs3825016) in hyperuricemia group, while only 2 persons have the same mutations in control group. CT mutation rate s of hURAT1 (rs7932775) and ABCG2 (rs3825016) in hyperuricemia group were 60.7% (17/28) and 50% (13/28) respectively, higher than that of control group (35.7% (5/14) and 42.8% (6/14)). What is more, Double SNP mutations in both hURAT1 (rs7932775) and ABCG2 (rs3825016) in hyperuricemia group w ere 25% (7/28), higher than that of control group (14.2%, 2/14). Conclusion: There are higher mutation rates of CT SNP in hURAT1 (rs7932775) and/or ABCG2 (rs3825016) in hyperuricemia group. We can conclude that hyperuricemia is a high risk factor in progress of CKD, which is necessary to take measures of decreasing serum uric acid to delay CKD progress.
- Srivastava, A., Kaze, A.D., Mcmullan, C.J., et al. (2018) Uric Acid and the Risks of Kidney Failure and Death in Individuals with CKD. American Journal of Kidney Diseases, 71, 362-370. https://doi.org/10.1053/j.ajkd.2017.08.017
- Li, C.C., Chien, T.M., Wu, W.J., et al. (2018) Uric Acid Stones Increase the Risk of Chronic Kidney Disease. Urolithiasis, 1-5. https://doi.org/10.1007/s00240-018-1050-1
- Garofalo, C., De Stefano, T., Vita, C., et al. (2018) Hyperuricaemia and Chronic Kidney Disease. Giornale italiano di nefrologia, 35, No. 1.
- Johnson, R.J., Bakris, G.L., Borghi, C., et al. (2018) Hyperuricemia, Acute and Chronic Kidney Disease, Hypertension, and Cardiovascular Disease: Report of a Scientific Workshop Organized by the National Kidney Foundation. American Journal of Kidney Diseases, 71, 851-865. https://doi.org/10.1053/j.ajkd.2017.12.009
- Dalbeth, N., Stamp, L.K. and Merriman, T.R. (2017) The Genetics of Gout: Towards Personalised Medicine? BMC Medicine, 15, 108. https://doi.org/10.1186/s12916-017-0878-5
- Major, T.J., Dalbeth, N., Stahl, E.A., et al. (2018) An Update on the Genetics of Hyperuricaemia and Gout. Nature Reviews Rheumatology, 14, 341-353. https://doi.org/10.1038/s41584-018-0004-x
- Merriman, T. (2017) Genomic Influences on Hyperuricemia and Gout. Rheumatic Disease Clinics of North America, 43, 389-399. https://doi.org/10.1016/j.rdc.2017.04.004
- Xu, L., Shi, Y., Zhuang, S., et al. (2017) Recent Advances on Uric Acid Transporters. Oncotarget, 8, 100852-100862. https://doi.org/10.18632/oncotarget.20135
- Jiri, M., Zhang, L., Lan, B., et al. (2016) Genetic Variation in the ABCG2 Gene Is Associated with Gout Risk in the Chinese Han Population. Clinical Rheumatology, 35, 159-163. https://doi.org/10.1007/s10067-015-3105-9
- Tan, P.K., Liu, S., Gunic, E., et al. (2017) Discovery and Characterization of Verinurad, a Potent and Specific Inhibitor of URAT1 for the Treatment of Hyperuricemia and Gout. Scientific Reports, 7, 665. https://doi.org/10.1038/s41598-017-00706-7
- Cho, S.K., Kim, S., Chung, J.Y., et al. (2015) Discovery of URAT1 SNPs and Association between Serum Uric Acid Levels and URAT1. BMJ Open, 5, e9360. https://doi.org/10.1136/bmjopen-2015-009360
- Sun, H., Qu, Q., Qu, J., et al. (2015) URAT1 Gene Polymorphisms Influence Uricosuric Action of Losartan in Hypertensive Patients with Hyperuricemia. Pharmacogenomics, 16, 855-863. https://doi.org/10.2217/pgs.15.52